Merck & Co., Inc. (BVL:MRKUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 1.23T +79.1% |
| Revenue (ttm) | 227.32B +4.6% |
| Net Income | 10.84B -80.7% |
| EPS | 4.35 -80.4% |
| Shares Out | n/a |
| PE Ratio | 113.50 |
| Forward PE | 16.61 |
| Dividend | 11.88 (2.32%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 148.69 |
| Day's Range | n/a |
| 52-Week Range | 78.55 - 150.66 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright
After Merck (MRK) presented Phase 2b data for tulisokibart in moderate-to-severe hidradenitis suppurativa at the EADV Congress and reported that it met the primary endpoint and will be advancing into…
Merck says experimental skin disease drug meets main goal in mid-stage study
Merck said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps,...
Merck says tulisokibart met primary, secondary endpoints in Phase 2b study
Merck (MRK) announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humaniz...
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b mul...
Merck price target raised to $180 from $155 at Scotiabank
Scotiabank raised the firm’s price target on Merck (MRK) to $180 from $155 and keeps an Outperform rating on the shares. The firm believes Merck’s products and pipeline remain underappreciated,…
US drugmakers turn to China for licensing deals
Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-develop...
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.
Merck enters global license agreement with SciBrunch Therapeutics for SPR2015
Merck (MRK) and SciBrunch Therapeutics announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D inhibitor. Under the agree...
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into ...
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday.
Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan
The Biologics License Application, or BLA, seeking accelerated approval in the U.S. for Daiichi Sankyo and Merck’s (MRK) ifinatamab deruxtecan for the treatment of adult patients with extensive-stage ...
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
TOKYO--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United Stat...
Merck, Eisai announce FDA approval of Welireg plus Lenvima
Merck (MRK) and Eisai (ESAIY) announced the U.S. FDA has approved the dual oral regimen of Welireg, Merck’s first-in-class oral hypoxia-inducible factor-2 alpha inhibitor, plus Lenvima, the orally ava...
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Compone...
FDA approves Welireg and Lenvima combo for ccRCC
The Food and Drug Administration approved Welireg from Merck (MRK) in combination with Lenvima from Eisai (ESAIY) for adults with advanced renal cell carcinoma with a clear cell component, or…
Merck's eye disease drug meets main goal in trial
Merck said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye.
Merck’s remigromig meets primary endpoint in Phase 2b/3 DME trial
Merck (MRK) announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema, or DME. BRUNELLO is the first of two Phase 2b/3 trials evaluating…
Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabet...
Merck says FDA approves update for U.S. product label for Winrevair
Merck (MRK) announced the U.S. FDA has approved an update to the U.S. product label for Winrevair for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. Winrevair, an…
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. p...
Pharmaceutical Companies Push Trump Administration to Protect China Deals
A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.
Merck says Japan’s MHLW approves Keytruda Qlex
Merck (MRK) announced the Ministry of Health, Labor and Welfare in Japan has approved Keytruda Qlex injection for subcutaneous use for all indications approved in Japan for Keytruda, Merck’s anti-PD-1...
Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA ...
Merck says CHMP adopts positive opinion on Keytruda/Padcev combination
Merck (MRK) announced the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combina...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (...